Success of innovative mental health research leads to exceptional additional support for new project from IMI, World’s biggest public-industry drug development partnership

Pers / media: OnderzoekAcademic

Description

Building on the success of innovative research by the PRISM project, the Innovative Medicine Initiative 2, a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has backed the program with funding for a new project to explore the underlying biology of Alzheimer’s disease, schizophrenia and Major Depressive Disorder (MDD). The new PRISM 2 (Psychiatric Ratings using Intermediate Stratified Markers 2) project aims to identify quantitative biological features common across the diseases, opening the possibility of developing targeted treatments irrespective of traditional diagnosis.

Periode22-jun-2021 → 28-jul-2021

Media-aandacht

3

Media-aandacht

  • TitelPRISM 2 to build on PRISM’s ground-breaking social withdrawal work
    Mate van erkenningInternational
    Media naam/outletIMI
    MediatypeWeb
    Land/RegioNetherlands
    Release datum28/07/2021
    BeschrijvingIMI’s PRISM project shed new light on social withdrawal, a common early symptom of many neurological disorders. Now PRISM 2 is set to build on its results.
    Producent / auteurIMI press release
    URLhttps://www.imi.europa.eu/news-events/newsroom/prism-2-build-prisms-ground-breaking-social-withdrawal-work
    PersonenMartien Kas
  • TitelNew project aims to identify quantitative biological features common across diseases
    Mate van erkenningInternational
    Media naam/outletNews-Medical.Net
    MediatypeWeb
    Land/RegioUnited Kingdom
    Release datum23/06/2021
    BeschrijvingBuilding on the success of innovative research by the PRISM project, the Innovative Medicine Initiative 2, a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has backed the program with funding for a new project to explore the underlying biology of Alzheimer's disease, schizophrenia and Major Depressive Disorder (MDD).
    Producent / auteurEmily Henderson
    URLhttps://www.news-medical.net/news/20210623/New-project-aims-to-identify-quantitative-biological-features-common-across-diseases.aspx
    PersonenMartien Kas
  • TitelSuccess of innovative mental health research leads to exceptional additional support for new project from IMI, World’s biggest public-industry drug development partnership
    Mate van erkenningInternational
    Media naam/outletAlphaGalileo
    MediatypeWeb
    Land/RegioUnited Kingdom
    Release datum22/06/2021
    BeschrijvingBuilding on the success of innovative research by the PRISM project, the Innovative Medicine Initiative 2, a joint undertaking between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has backed the program with funding for a new project to explore the underlying biology of Alzheimer’s disease, schizophrenia and Major Depressive Disorder (MDD). The new PRISM 2 (Psychiatric Ratings using Intermediate Stratified Markers 2) project aims to identify quantitative biological features common across the diseases, opening the possibility of developing targeted treatments irrespective of traditional diagnosis.
    Producent / auteurPRISM
    URLhttps://www.alphagalileo.org/en-gb/Item-Display/ItemId/209716
    PersonenMartien Kas